CymaBay Therapeutics Inc (CBAY) - Financial and Strategic SWOT Analysis Review

  • ID: 4284577
  • SWOT Analysis
  • 42 pages
  • GlobalData
  • CymaBay Therapeutics
1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Esperion Therapeutics Inc
  • Pfizer Inc
  • MORE
CymaBay Therapeutics Inc (CBAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Arhalofenate, an oral small molecule intended for the treatment of Gout flares. It also develops MBX-2982 and MBX-8025 for patients with type 2 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

CymaBay Therapeutics Inc Key Recent Developments

Dec 04, 2017: CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel
Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates
Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Jun 26, 2017: CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance
May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Esperion Therapeutics Inc
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • CymaBay Therapeutics Inc - Key Facts
  • CymaBay Therapeutics Inc - Key Employees
  • CymaBay Therapeutics Inc - Key Employee Biographies
  • CymaBay Therapeutics Inc - Major Products and Services
  • CymaBay Therapeutics Inc - History
  • CymaBay Therapeutics Inc - Company Statement
  • CymaBay Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • CymaBay Therapeutics Inc - Business Description
  • R&D Overview
  • CymaBay Therapeutics Inc - Corporate Strategy
  • CymaBay Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • CymaBay Therapeutics Inc - Strengths
  • CymaBay Therapeutics Inc - Weaknesses
  • CymaBay Therapeutics Inc - Opportunities
  • CymaBay Therapeutics Inc - Threats
  • CymaBay Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • CymaBay Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Dec 04, 2017: CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel
  • Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates
  • Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  • Jun 26, 2017: CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance
  • May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update
  • Mar 29, 2017: CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.
  • Mar 23, 2017: CymaBay Reports Fourth Quarter and Year End 2016 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • CymaBay Therapeutics Inc, Key Facts
  • CymaBay Therapeutics Inc, Key Employees
  • CymaBay Therapeutics Inc, Key Employee Biographies
  • CymaBay Therapeutics Inc, Major Products and Services
  • CymaBay Therapeutics Inc, History
  • CymaBay Therapeutics Inc, Key Competitors
  • CymaBay Therapeutics Inc, Ratios based on current share price
  • CymaBay Therapeutics Inc, Annual Ratios
  • CymaBay Therapeutics Inc, Annual Ratios (Cont...1)
  • CymaBay Therapeutics Inc, Interim Ratios
  • CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • CymaBay Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • CymaBay Therapeutics Inc, Performance Chart (2012 - 2016)
  • CymaBay Therapeutics Inc, Ratio Charts
  • CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • Esperion Therapeutics Inc
  • Bristol-Myers Squibb Co
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll